Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL8553287 | 0.98 | TAAR1 (0.30) | TAAR1SYKAURKB | |
| SCHEMBL6186423 | 0.89 | TAAR1 (0.35) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2920630 | 0.89 | CYP1A2 (0.34) | — | |
| SCHEMBL8553122 | 0.87 | RAD52 (0.35) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| Hydrazine SCHEMBL8552818 | 0.87 | TAAR1 (0.34) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| Hydrazine SCHEMBL8554894 | 0.85 | RAD52 (0.35) | TAAR1 | |
| SCHEMBL8560784 | 0.85 | RAD52 (0.35) | TAAR1 | |
| SCHEMBL8555780 | 0.85 | RAD52 (0.35) | TAAR1 | |
| Hydrazine SCHEMBL8557324 | 0.84 | RAD52 (0.34) | TAAR1 | |
| Hydrazine SCHEMBL8561436 | 0.84 | RAD52 (0.34) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076923-A | Printing original plate for photosensitive resin relief printing plate and printing plate | 东洋纺MC株式会社 | 2024-05-24 | — | — | CN | disclosed |
| CN-110078664-B | Phosgene fluorescent probe and preparation method thereof | 长江大学 | 2023-07-21 | — | — | CN | disclosed |
| CN-104447702-B | A kind of amido replaces Bouchardatine derivant and its preparation method and application | 中山大学 | 2016-12-07 | — | — | CN | disclosed |
| CN-104447702-A | Amidogen substituted Bouchardatine derivative as well as preparation method and application thereof | UNIV SUN YAT SEN | 2015-03-25 | — | — | CN | disclosed |
| US-20120070620-A1 | SELF-ADHESIVE FRAME | SAINT-GOBAIN PERFORMANCE PLASTICS CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0575954-B1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI SRL (IT) | 1998-09-02 | — | — | EP | disclosed |
| US-5424451-A | Used as cholinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| US-5302593-A | Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | disclosed |
| US-3943107-A | Processable high temperature polymers prepared from amine terminated polymers and cyanamides of polyfunctional secondary amines | CIBA-GEIGY CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | TAAR1 830/4885SYK 1595/4885AURKB 4321/4885 |
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | TAAR1 2587/4885SYK 1912/4885AURKB 3808/4885 |
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | TAAR1 4074/4885SYK 929/4885AURKB 4219/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | TAAR1 2366/4885SYK 3153/4885AURKB 2255/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | TAAR1 4603/4885SYK 981/4885AURKB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.